Small clinical trials have indicated benefit of treatment with IL-1ra in reducing the inflammatory response after acute coronary syndromes in the MRC IL-1 study [44] and a series of studies carried out by the group of Antonio Abbate targeting myocardial infarction and heart failure [18]. This evidence concerns the gene IL1A and acute coronary syndrome.